Why the study?
Prevention of perioperative cardiac complications in noncardiac surgery remains an urgent complex medical challenge with a limited spectrum of recommended cardioprotective agents.
Exogenous phosphocreatine is highlighted as a potentially effective and safe cardioprotective agent for high-risk patients undergoing noncardiac surgery, addressing the limitations of currently available therapies.
Answers are grounded in this paper and cite their sources.
Exogenous phosphocreatine remains investigational for cardioprotection; leaves open its role pending randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kozlov Ia (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: